PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) announced that CEO David H. Mack, Ph.D., will participate in a panel on lung cancer at the 42nd Annual Cowen Health Care Conference from March 7-9, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) announced that CEO David H. Mack, Ph.D., will participate in a panel on lung cancer at the 42nd Annual Cowen Health Care Conference from March 7-9, 2022. The panel discussion is scheduled for March 9, 2022, from 9:10 AM to 10:10 AM EST. The company, focused on developing small molecule therapies targeting p53 mutations, aims to connect with institutional investors during the conference.
PMV Pharma was founded to innovate in oncology, leveraging over 40 years of research into p53 biology.
Details
News Market Reaction – PMVP
The recorded move for PMVP in the trading session of this news was -1.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CRANBURY, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will participate in a panel discussion on lung cancer at the 42nd Annual Cowen Health Care Conference taking place virtually March 7-9, 2022. The company will also be available to meet one-on-one with institutional investors at the conference.
Details on the panel can be found below.
Cowen’s 42nd Annual Health Care Conference
| Date: | Wednesday, March 9, 2022 |
| Time: Format: | 9:10 AM – 10:10 AM EST Corporate Panel Discussion |
| Title: | Lung Cancer |
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.
Contact
For Investors:
Winston Kung
Chief Financial Officer
investors@pmvpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.